Physician profile
Frank Sharp
NPI 1801880711
$6,683.33
in general payments reported to CMS, 2019-2025
52 companies · $849 in 2025
The $849 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,496 · 2020: $576 · 2021: $743 · 2022: $1,135 · 2023: $877 · 2024: $1,008 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,734.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $784.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $622.35 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $478.89 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $442.31 | 2019-2024 | Verquvo, Belsomra |
| Amgen INC. | $405.99 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $354.14 | 2019-2023 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $297.68 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $281.50 | 2019-2023 | |
| Lilly USA, LLC | $230.19 | 2019-2025 | Zepbound, Mounjaro, Emgality |
| Amarin Pharma, INC. | $228.76 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $178.09 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.23 | 2019-2024 | Jardiance |
| Biohaven Pharmaceutical Holding Company Ltd. | $173.08 | 2022 | |
| Exact Sciences Corporation | $165.82 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $137.12 | 2021-2025 | Veozah, Myrbetriq |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.